These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15813090)

  • 21. [Chronic heart insufficiency should be treated also with spironolactone].
    Kjeldsen KP; Nørgaard A; Thygesen K
    Ugeskr Laeger; 1999 Sep; 161(37):5132. PubMed ID: 10523942
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New hope for heart failure.
    DeMaria A
    Health News; 1999 Sep; 5(11):1-2. PubMed ID: 10513252
    [No Abstract]   [Full Text] [Related]  

  • 24. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of spironolactone on C-reactive protein levels in patients with heart disease.
    Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD
    Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
    Glick HA; Orzol SM; Tooley JF; Remme WJ; Sasayama S; Pitt B
    Cardiovasc Drugs Ther; 2002 Jan; 16(1):53-9. PubMed ID: 12085979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.
    Masoudi FA; Havranek EP; Wolfe P; Gross CP; Rathore SS; Steiner JF; Ordin DL; Krumholz HM
    Am Heart J; 2003 Aug; 146(2):250-7. PubMed ID: 12891192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
    Gao X; Peng L; Adhikari CM; Lin J; Zuo Z
    J Card Fail; 2007 Apr; 13(3):170-7. PubMed ID: 17448413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spironolactone in left-sided heart failure: how does it fit in?
    Margo KL; Luttermoser G; Shaughnessy AF
    Am Fam Physician; 2001 Oct; 64(8):1393-8. PubMed ID: 11681781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An old drug provides surprising benefits for heart-failure patients.
    Harv Heart Lett; 1999 Dec; 10(4):5-7. PubMed ID: 10564892
    [No Abstract]   [Full Text] [Related]  

  • 32. [Aldosterone antagonist].
    Yamazaki T
    Nihon Rinsho; 2006 May; 64(5):917-20. PubMed ID: 16689374
    [No Abstract]   [Full Text] [Related]  

  • 33. A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study.
    Koch E; Otarola A; Kirschbaum A
    J Epidemiol Community Health; 2005 Nov; 59(11):1000-6. PubMed ID: 16234430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aldactone in the complex treatment of circulatory insufficiency in elderly patients].
    Morozov KA; Goriainova AN
    Kardiologiia; 1976 Nov; 16(11):150-1. PubMed ID: 1011458
    [No Abstract]   [Full Text] [Related]  

  • 35. Spironolactone (aldactone) bodies: concentric lamellar formations in the adrenal cortices of patients treated with spironolactone.
    Davis DA; Medline NM
    Am J Clin Pathol; 1970 Jul; 54(1):22-32. PubMed ID: 5504616
    [No Abstract]   [Full Text] [Related]  

  • 36. The Significance of Râles.
    Macdermot HE
    Can Med Assoc J; 1928 Jul; 19(1):87-8. PubMed ID: 20316939
    [No Abstract]   [Full Text] [Related]  

  • 37. THE CLASSIFICATION OF RALES.
    Kinghorn HM
    Can Med Assoc J; 1932 Apr; 26(4):438-45. PubMed ID: 20318684
    [No Abstract]   [Full Text] [Related]  

  • 38. [Randomized Aldactone Evaluation Study (RALES)].
    Uchida K; Nakano S; Kigoshi T
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():330-5. PubMed ID: 15813090
    [No Abstract]   [Full Text] [Related]  

  • 39. [The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):987-8. PubMed ID: 10488324
    [No Abstract]   [Full Text] [Related]  

  • 40. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.